ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Clinical trials for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE explained in plain language.
Never miss a new study
Get alerted when new ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE trials appear
Sign up with your email to follow new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a stem cell boost keep T-Cell lymphoma away longer?
Disease control Recruiting nowThis study looks at whether giving high-dose chemotherapy followed by a transplant of the patient's own stem cells can help people with peripheral T-cell lymphoma stay in remission longer than just watching and waiting. About 294 adults aged 18 to 75 who are in their first comple…
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Phase: PHASE3 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Supercharged donor cells take on lymphoma in early trial
Disease control Recruiting nowThis early-phase trial tests a new approach for people with certain lymphomas that have come back or not responded to treatment. Researchers take immune cells from healthy donors, modify them to recognize and attack CD30-positive cancer cells, and add a molecule (C7R) to boost th…
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New pill may keep rare lymphoma in check after chemo
Disease control Recruiting nowThis study tests whether the drug golidocitinib can help keep peripheral T-cell lymphoma (a rare blood cancer) from coming back after initial chemotherapy. About 136 adults who had a good response to first treatment but cannot or choose not to have a stem cell transplant will tak…
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Can a stem cell transplant stop T-Cell lymphoma from returning?
Disease control Recruiting nowThis study looks at whether a stem cell transplant (using a patient's own cells) after successful first treatment can help control peripheral T-cell lymphoma. About 160 people will either get the transplant or just be monitored. The goal is to see if the transplant delays the can…
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Stem cell showdown: donor or self? new trial aims to improve lymphoma outcomes
Disease control Recruiting nowThis study compares two types of stem cell transplants for people with peripheral T-cell lymphoma whose cancer only partially responded to first treatment. One group receives their own stem cells, the other receives cells from a matched donor. The goal is to see which approach le…
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Massive T-Cell lymphoma database aims to unlock new insights
Knowledge-focused Recruiting nowThis study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC